Supriya Lifescience Ltd

Stage 3 · Topping · week 2

As of 20 Nov 2026, Supriya Lifescience is in Stage 3, the topping phase, now in week 2 (since 12 Nov 2026). It closed at ₹620, 41.1% below its 52-week high and below its 200-day average, which is rising. In Health Care, 34.7% of stocks are in Stage 2.

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. More about the company

₹620.2
Close, 20 Nov 2026
-0.78% on the day
₹4,991 Cr · Small cap
Market DowntrendHealth Care 34.7% in Stage 2-11.4 pts / 20dPharmaceuticals 42.4%-13.9 pts

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

RS rank

Edge

—

SUPRIYA's uptrend is tiring: 2 weeks into a top. A topping stock either breaks back out or rolls over into a decline, and the next few weeks usually settle which.

Its relative strength is 39 of 99, below the middle among NSE stocks over the past year. Pharmaceuticals ranks 7 of 106 industries by the strength of its stocks, among the leaders.

Is SUPRIYA early, or has it already run? Pro answers that for every NSE stock, after every close.

Loading price chart…
Stage Cycle Timeline2023-08-24 → 2026-11-20
S2 59w
2023-08-242026-11-20
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 9w → S3 8w → S2 59w → S3 9w → S2 3w → S3 2w → S2 5w → S3 3w → S2 3w → S4 9w → S1 1w → S2 13w → S3 5w → S4 12w → S1 3w → S2 11w → S3 5w → S2 6w → S3 1w current
Total tracked: 168 weeks across 19 stage runs.

SUPRIYA among Pharmaceuticals90th of 118 by relative strength

All 118 →
Stocks in Pharmaceuticals ranked by relative strength, with stage and one-month change
#StockStageRS1M
1BLISSGVSStage 2 · wk 4999+4.6%
2KPLStage 2 · wk 4499+20.5%
3FREDUNStage 2 · wk 3398+24.0%
4VENUSREMStage 3 · wk 1098−1.5%
5RUBICONStage 3 · wk 498+18.7%
6SAKARStage 2 · wk 5598+13.1%
7BAFNAPHStage 2 · wk 2398+1.9%
8INDSWFTLABStage 2 · wk 2398−7.4%
…90SUPRIYAStage 3 · wk 239−26.4%
vs 52W High
-41.1%
₹553.4 lo₹1,052.5 hi
41.1% below 52W high, weakening from peak
The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.
Stage Maturity
Week 2
1w13w26w
Week 2, early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
-20.8%
200 DMA: ₹783.2 · rising
The stock has lost its 200-day average. In a topping stock that adds to the Stage 4 risk.
Rel Volume
0.38x
vs 50-day avg
Volume was well below average. Quiet sessions say little in a topping stock. Volume on the down days matters more.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-26.4%
3M
-21.3%
6M
-14.5%
YTD
-17.5%
1Y
-21.2%
Sector
Health Care
↓ Peaking
Stage 2%
34.7%
20d Δ
-11.4pp
1M return
+11.5%
3M return
+3.8%
Sector Stage-2 % · last 20 days
Sector has 58 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
42.4%
20d Δ
-13.9pp
1M return
+8.3%
3M return
+2.1%
Industry Stage-2 % · last 20 days
Industry has 48 Stage 2 leaders. See Pharmaceuticals Stage 2 →

Mutual fund holdings

Held by 10 mutual funds in portfolios to October 2026: 3 active funds and 7 index funds and ETFs.

In October, no active fund changed its holding.

Largest active holders, by weight in the fund
All 10 funds and what each did in October

Mutual funds holding SUPRIYA: the ten largest and the month’s moves →

Fund details on DiscoverMF

Scan Membership
Not in any scan now.
Last appeared 7 Oct 2026
Last appeared 30 Sep 2026
6 appearances in the last 60 days.
Recent Stage Timeline
2026-11-20S3
Wk 2 · Vol 0.38x
2026-11-19S3
Wk 2 · Vol 0.57x
2026-11-18S3
Wk 1 · Vol 0.55x
2026-11-17S3
Wk 1 · Vol 0.79x
2026-11-16S3
Wk 1 · Vol 0.49x
2026-11-13S3
Wk 1 · Vol 0.70x
2026-11-12S32→3
Wk 1 · Vol 1.14x
2026-11-11S2
Wk 6 · Vol 2.28x
2026-11-09S2
Wk 6 · Vol 10.53x
2026-11-06S2
Wk 6 · Vol 7.79x
2026-11-05S2
Wk 5 · Vol 0.58x
2026-11-04S2
Wk 5 · Vol 0.47x
Moving averages & range
50 DMA
₹841.5
200 DMA
₹783.2
52W High
₹1,052.5
52W Low
₹553.4
5D Low
₹614.8
Resistance levels (recent highs)
20d High
₹869.6
60d High
₹1,000.9
120d High
₹1,052.5
250d High
₹1,052.5
Next resistance
+40.2%
to 20d High
P/E (TTM)
28.2
Forward 22.9
Earnings Growth (YoY)
-42.1%
Revenue +3.2%
ROE
+15.2%
Profit margin +20.2%
Dividend Yield
0.16%
P/B 4.0

Supriya Lifescience: quick answers

What stage is Supriya Lifescience in?

As of 20 Nov 2026, Supriya Lifescience (SUPRIYA) is in Stage 3, the topping phase. It entered Stage 3 on 12 Nov 2026 and is in week 2. What the four stages mean

Is Supriya Lifescience in an uptrend?

Its uptrend has stalled. Supriya Lifescience is in Stage 3, the topping phase that follows an advance. It trades 20.8% below its 200-day average, which is rising.

How far is Supriya Lifescience from its 52-week high?

Supriya Lifescience closed at ₹620 on 20 Nov 2026, 41.1% below its 52-week high of ₹1,053. Its 52-week low is ₹553.

How has Supriya Lifescience performed over the past year?

As of 20 Nov 2026, Supriya Lifescience is down 21.2% over the past year and down 17.5% so far in 2026.

Which sector and industry is Supriya Lifescience in?

Supriya Lifescience is in the Pharmaceuticals industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Pharmaceuticals

About this companyHealth Care· Pharmaceuticals

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.